A detailed history of Syntax Advisors, LLC transactions in Vertex Pharmaceuticals Inc stock. As of the latest transaction made, Syntax Advisors, LLC holds 678 shares of VRTX stock, worth $340,661. This represents 0.41% of its overall portfolio holdings.

Number of Shares
678
Previous 690 1.74%
Holding current value
$340,661
Previous $242,000 2.89%
% of portfolio
0.41%
Previous 0.37%

Shares

8 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2023

Nov 13, 2023

SELL
$338.18 - $362.46 $4,058 - $4,349
-12 Reduced 1.74%
678 $235,000
Q2 2023

Aug 14, 2023

SELL
$314.42 - $351.91 $45,590 - $51,026
-145 Reduced 17.37%
690 $242,000
Q1 2023

May 15, 2023

BUY
$283.23 - $323.1 $17,843 - $20,355
63 Added 8.16%
835 $263,000
Q4 2022

Feb 14, 2023

SELL
$285.76 - $321.48 $29,433 - $33,112
-103 Reduced 11.77%
772 $222,000
Q3 2022

Nov 14, 2022

SELL
$273.83 - $305.53 $19,168 - $21,387
-70 Reduced 7.41%
875 $253,000
Q2 2022

Aug 12, 2022

SELL
$234.96 - $292.55 $6,343 - $7,898
-27 Reduced 2.78%
945 $266,000
Q1 2022

May 11, 2022

SELL
$221.42 - $260.97 $61,997 - $73,071
-280 Reduced 22.36%
972 $254,000
Q4 2021

Feb 14, 2022

BUY
$177.01 - $223.45 $221,616 - $279,759
1,252 New
1,252 $275,000

Others Institutions Holding VRTX

About VERTEX PHARMACEUTICALS INC


  • Ticker VRTX
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 256,691,008
  • Market Cap $129B
  • Description
  • Vertex Pharmaceuticals Incorporated, a biotechnology company, engages in developing and commercializing therapies for treating cystic fibrosis. The company markets SYMDEKO/SYMKEVI, ORKAMBI, and KALYDECO to treat patients with cystic fibrosis who have specific mutations in their cystic fibrosis transmembrane conductance regulator gene; and TRIKAF...
More about VRTX
Track This Portfolio

Track Syntax Advisors, LLC Portfolio

Follow Syntax Advisors, LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Syntax Advisors, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Syntax Advisors, LLC with notifications on news.